135 related articles for article (PubMed ID: 38288741)
1. Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study.
Farge D; Loisel S; Resche-Rigon M; Lansiaux P; Colmegna I; Langlais D; Charles C; Pugnet G; Maria ATJ; Chatelus E; Martin T; Hachulla E; Kheav VD; Lambert NC; Wang H; Michonneau D; Martinaud C; Sensebé L; Cras A; Tarte K
Lancet Rheumatol; 2022 Feb; 4(2):e91-e104. PubMed ID: 38288741
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA
Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339
[TBL] [Abstract][Full Text] [Related]
4. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
[TBL] [Abstract][Full Text] [Related]
5. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).
Perico N; Remuzzi G; Griffin MD; Cockwell P; Maxwell AP; Casiraghi F; Rubis N; Peracchi T; Villa A; Todeschini M; Carrara F; Magee BA; Ruggenenti PL; Rota S; Cappelletti L; McInerney V; Griffin TP; Islam MN; Introna M; Pedrini O; Golay J; Finnerty AA; Smythe J; Fibbe WE; Elliman SJ; O'Brien T;
J Am Soc Nephrol; 2023 Oct; 34(10):1733-1751. PubMed ID: 37560967
[TBL] [Abstract][Full Text] [Related]
6. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
Connick P; Kolappan M; Crawley C; Webber DJ; Patani R; Michell AW; Du MQ; Luan SL; Altmann DR; Thompson AJ; Compston A; Scott MA; Miller DH; Chandran S
Lancet Neurol; 2012 Feb; 11(2):150-6. PubMed ID: 22236384
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
8. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD
Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077
[TBL] [Abstract][Full Text] [Related]
9. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.
Skrahin A; Ahmed RK; Ferrara G; Rane L; Poiret T; Isaikina Y; Skrahina A; Zumla A; Maeurer MJ
Lancet Respir Med; 2014 Feb; 2(2):108-22. PubMed ID: 24503266
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease.
Schiess M; Suescun J; Doursout MF; Adams C; Green C; Saltarrelli JG; Savitz S; Ellmore TM
Mov Disord; 2021 Aug; 36(8):1825-1834. PubMed ID: 33772873
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial.
Granel B; Daumas A; Jouve E; Harlé JR; Nguyen PS; Chabannon C; Colavolpe N; Reynier JC; Truillet R; Mallet S; Baiada A; Casanova D; Giraudo L; Arnaud L; Veran J; Sabatier F; Magalon G
Ann Rheum Dis; 2015 Dec; 74(12):2175-82. PubMed ID: 25114060
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.
Ebata S; Yoshizaki A; Oba K; Kashiwabara K; Ueda K; Uemura Y; Watadani T; Fukasawa T; Miura S; Yoshizaki-Ogawa A; Asano Y; Okiyama N; Kodera M; Hasegawa M; Sato S
Lancet Rheumatol; 2021 Jul; 3(7):e489-e497. PubMed ID: 38279402
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
[TBL] [Abstract][Full Text] [Related]
15. Intravenous transplantation of bone marrow-derived mesenchymal stromal cells in patients with multiple sclerosis, a phase I/IIa, double blind, randomized controlled study.
Nabavi SM; Karimi S; Arab L; Aghdami N; Joghtaei N; Maroufizadeh S; Jarooghi N; Bolurieh T; Abbasi F; Mardpour S; Azimyian V; Moeininia F; Sanjari L; Hosseini SE; Vosough M
Mult Scler Relat Disord; 2023 Oct; 78():104895. PubMed ID: 37515913
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow transplantation: a new strategy for intractable diseases.
Ikehara S
Drugs Today (Barc); 2002 Feb; 38(2):103-11. PubMed ID: 12532188
[TBL] [Abstract][Full Text] [Related]
18. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study.
Baak LM; Wagenaar N; van der Aa NE; Groenendaal F; Dudink J; Tataranno ML; Mahamuud U; Verhage CH; Eijsermans RMJC; Smit LS; Jellema RK; de Haan TR; Ter Horst HJ; de Boode WP; Steggerda SJ; Prins HJ; de Haar CG; de Vries LS; van Bel F; Heijnen CJ; Nijboer CH; Benders MJNL
Lancet Neurol; 2022 Jun; 21(6):528-536. PubMed ID: 35568047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
